|Title:||Activity of liposomal Taxol against breast cancer cells / by Melanie Heney.|
|Authors:||Heney, Melanie A.|
|Keywords:||Paclitaxel;Breast Cancer Research;Liposomes|
|Abstract:||"Taxol (paclitaxel) is one of the most effective chemotherapeutic agents used for the treatment of multiple cancers, including breast, ovarian, and, non-small-cell lung cancer. However, development of taxol resistance with prolonged use is common, requiring the use of the chemotherapeutic agent in combination with other treatments. In addition to the development of resistance, taxol is difficult to administer due to its high lipophilicity, and it requires solubilization with Cremophor EL (polyethoxylated castor oil) and ethanol, which often lead to adverse side-effects, including life-threatening anaphylaxis. Incorporation of taxol in DPPC:DMPG (dimyristoyl phosphatidylcholine: dimyristoyl phosphatidylglycerol) liposomes may not only eliminate the adverse reactions associated with the Cremophor EL vehicle, but also decrease other toxicities that arise from the drug's action in non-targeted tissues.|
|Degree Name :||M.Sc.|
|Appears in Collections:||Retrospective theses|
Files in This Item:
There are no files associated with this item.
Items in Knowledge Commons are protected by copyright, with all rights reserved, unless otherwise indicated.